{'Year': '2017', 'Month': 'Oct', 'Day': '01'}
Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
To determine whether prospective testing for HLA-B*58:01, as a strategy to prevent serious adverse reactions to allopurinol in patients with gout, is cost-effective from the perspective of the National Health Service in the UK.